Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

Inclusion Criteria:

• 3. Patients diagnosed with HCC by histological examination; 4) According to ChinaLiver Cancer Staging (CNLC) -- Guidelines for the Diagnosis and Treatment of primaryliver Cancer of the National Health Commission of the People's Republic of China (2022edition), patients with stage Ia and stage Ib ⅱA; 5) Undergoing radical resection ofHCC; 6) For patients with hepatocellular carcinoma diagnosed by pathology afterradical resection, the clinical and pathological characteristics meet one of thefollowing conditions: A. tumor ≥5cm; B. Pathology suggested MVI (microvascularinvasion); C. Pathology suggested satellite foci or sub-foci; D. Multiple tumors (number of tumors ≥2); E. AFP & GT; 20 mu g/L; F. Accompanied by hepatic capsuleinvasion; 7) ECOG score 0 or 1; Child-pugh liver function score A/B (≤7); 8)Neutrophil count ≥1.5×109/L, lymphocyte count ≥1.1×109/L, platelet count ≥80×109/L;Cardiac echocardiography showed that cardiac ejection fraction ≥50%, and 12-lead ECGshowed no obvious abnormalities. Oxygen saturation ≥90%; Creatinine clearance rate CGformula ≥50 mL/min; ALT and AST 2.5 x ULN or less; Serum total bilirubin ≤1.5×ULN; 9)The estimated survival time is more than 6 months; 10) Fertile men or women with thepossibility of becoming pregnant agree to use effective contraceptive methods (e.g.,oral contraceptives, intrauterine devices, controlled sexual desire or barriercontraception combined with spermicide) during the trial and to continue contraceptionfor 3 months after completion of treatment.

Exclusion Criteria:

• 1. Pregnant or lactating women; 2) Previous systemic treatment: cytotoxic chemotherapydrugs within 3 months, targeted drugs within 2 months, interferon and/or interleukin-2within 3 months, and leukocyte raising drugs within 2 weeks; Have been treated withdrugs that target immune regulatory points; 3) Have used immunosuppressive agents (e.g., azathioprine, 6-mercaptopurine, cyclosporine, tisirolimus, everolimus,rapamycin, etc.); Long-term use of corticosteroids; 4) History of thromboembolismwithin the last 3 months or high risk of pulmonary embolism; 5) Previous use of DC-CIKor CIK cells, autologous RAK/LAK cells or other adoptive immunotherapy; 6) A historyof other malignant diseases in the last 5 years (except cured skin cancer andcarcinoma in situ of the cervix); 7) Uncontrolled epilepsy, central nervous systemdiseases, cerebrovascular accidents, or accompanied by other uncontrolled diseases; Ahistory of mental disorders; 8) Clinically severe heart disease (NYHA) grade II ormore congestive heart failure or severe arrhythmias requiring medical intervention; 9)Interstitial lung disease ≥2 degrees; 10) Accompanied by fever or infection; 11)Autoimmune diseases, including uncontrolled hypothyroidism and hyperthyroidism; 12)HIV/AIDS or syphilis antibody positive; 13) Allergic to any interferon andinterleukin-2 preparations; 14) Participating in other trials within 4 weeks beforeenrollment; 15) Poor compliance or conditions deemed inappropriate for study inclusionby the investigator.